Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$67.72 USD
-2.37 (-3.38%)
Updated Nov 6, 2025 04:00 PM ET
After-Market: $67.77 +0.05 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its growth rate over the past 12 months. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MIRM 67.72 -2.37(-3.38%)
Will MIRM be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for MIRM based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for MIRM
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
MIRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MIRM
MIRM forms 20 Day Moving Average Resistance on November 5
Mirum Pharmaceuticals (MIRM): Cantor Fitzgerald Raises Price Target to $95 | MIRM Stock News
Stifel Nicolaus Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)
Mirum Pharmaceuticals (MIRM) Receives a Buy from Evercore ISI
Mirum Pharmaceuticals (MIRM) Gets a Buy from Morgan Stanley